Fox Business·2025-12-01 18:43Core Insights - Eli Lilly has announced new price cuts for its weight loss drug Zepbound, reducing costs to enhance patient access and promote the use of its digital healthcare platform, LillyDirect [1][2] - The price for single-dose vials of Zepbound will now be $299 per month, down from $349, while the 5-milligram dose will be priced at $399, reduced from $499 [1][2] - The company aims to expand access for patients lacking insurance or adequate coverage through its Zepbound Self Pay Journey Program [2][9] Pricing Details - Regular monthly prices for Zepbound when not purchased through the Self-Pay Journey Program are significantly higher, ranging from $599 for 7.5 milligrams to $1,049 for 15 milligrams [5] - Multi-dose pens for Zepbound are expected to be priced at $299 for the lowest dose, with additional doses up to $449, pending FDA approval [6][8] Competitive Landscape - Eli Lilly and Novo Nordisk are both launching direct-to-consumer platforms to reduce barriers for new patients, enhancing their competitive positions in the weight loss drug market [9][11] - Novo Nordisk's platform, NovoCare Pharmacy, was launched in March to assist patients who cannot afford standard prices or lack insurance coverage for its weight loss drugs [11]